- Kim, Jong Wook;
- Abudayyeh, Omar O;
- Yeerna, Huwate;
- Yeang, Chen-Hsiang;
- Stewart, Michelle;
- Jenkins, Russell W;
- Kitajima, Shunsuke;
- Konieczkowski, David J;
- Medetgul-Ernar, Kate;
- Cavazos, Taylor;
- Mah, Clarence;
- Ting, Stephanie;
- Van Allen, Eliezer M;
- Cohen, Ofir;
- Mcdermott, John;
- Damato, Emily;
- Aguirre, Andrew J;
- Liang, Jonathan;
- Liberzon, Arthur;
- Alexe, Gabriella;
- Doench, John;
- Ghandi, Mahmoud;
- Vazquez, Francisca;
- Weir, Barbara A;
- Tsherniak, Aviad;
- Subramanian, Aravind;
- Meneses-Cime, Karina;
- Park, Jason;
- Clemons, Paul;
- Garraway, Levi A;
- Thomas, David;
- Boehm, Jesse S;
- Barbie, David A;
- Hahn, William C;
- Mesirov, Jill P;
- Tamayo, Pablo
The systematic sequencing of the cancer genome has led to the identification of numerous genetic alterations in cancer. However, a deeper understanding of the functional consequences of these alterations is necessary to guide appropriate therapeutic strategies. Here, we describe Onco-GPS (OncoGenic Positioning System), a data-driven analysis framework to organize individual tumor samples with shared oncogenic alterations onto a reference map defined by their underlying cellular states. We applied the methodology to the RAS pathway and identified nine distinct components that reflect transcriptional activities downstream of RAS and defined several functional states associated with patterns of transcriptional component activation that associates with genomic hallmarks and response to genetic and pharmacological perturbations. These results show that the Onco-GPS is an effective approach to explore the complex landscape of oncogenic cellular states across cancers, and an analytic framework to summarize knowledge, establish relationships, and generate more effective disease models for research or as part of individualized precision medicine paradigms.